今天,我们来看看这本SCI期刊:Expert Review of Clinical Pharmacology。从现有的记录来看,Expert Review of Clinical Pharmacology 的2021年影响因子(JCR2020)是5.045,2020年是3.481,比2020年增长1.564,增长比例44.93%。
期刊基本信息
关于此刊的具体情况,大家可以看看:
https://www.tandfonline.com/journals/ierj20
来自期刊官网
期刊接受范围
Expert Review of Clinical Pharmacology 的收稿范围,期刊是如此介绍的(截取部分内容),详情请阅读:
https://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ierj20
Expert Review of Clinical Pharmacology [ISSN 1751-2433]; [e-ISSN 1751-2441] is a MEDLINE-indexed, international journal publishing rigorously peer-reviewed review articles and original papers on all aspects of clinical safety, tolerability, efficacy and therapeutic applications.
The journal also covers toxicity issues, adverse reactions, pharmacoeconomics, and societal issues. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing.
期刊接受时间
对于 Expert Review of Clinical Pharmacology 的接受时间,我们看了几篇新近发表的:只需1-7个月就可以接受!
- Received 20 April 2021,Accepted 27 October 2021
- Received 4 October 2021,Accepted 16 December 2021
- Received 16 June 2021,Accepted 18 October 2021
- Received 17 February 2021,Accepted 23 September 2021
- Received 14 September 2021,Accepted 19 October 2021
- Received 6 May 2021,Accepted 28 September 2021
- Received 9 April 2021,Accepted 23 September 2021
- Received 26 May 2021,Accepted 1 September 2021
期刊年发文量
对于 Expert Review of Clinical Pharmacology 的发文量,2018年发文100篇,2019年发文108篇,2020年发文110多篇,2021年发文110多篇。
影响因子
即时影响因子计算发现,2022年3月7日,3.880分。按照常规期刊计算方法,以及往年经验,在2022年6月份公布的IF中,它或许在4分左右!但因为距离2022年6月份时间还太久,因此具体IF分值,3月底的预测会准确一些!
投稿网址及网页界面
想必大家对如何投稿,也很感兴趣,这里我们简单介绍一下投稿界面
https://mc.manuscriptcentral.com/erf
如果还没有注册过账户,只需点击“Create an Account”注册账户即可!
有5+分以上发表要求的,来看看这个潜力股的SCI期刊吧!
版权声明:本文转自“51选刊”,文章转载只为学术传播,不代表本号观点,无商业用途,版权归原作者所有,如涉及侵权问题,请联系我们,我们将及时修改或删除。
添加微信获取最新优惠、出版政策、课程直播信息,随时咨询客服/编辑,了解更多实时资讯